ArriVent shares plunge as FURVENT miss shifts attention to PACC lung cancer and ADC pipeline

ArriVent BioPharma lost more than half its market value after firmonertinib failed the primary endpoint in the pivotal FURVENT study, sharply reducing expectations that the oral EGFR inhibitor could challenge the established first-line treatment for EGFR exon 20 insertion-mutant lung cancer. Shares fell roughly 58% to around $12 after closing the previous session at $28.46, marking the steepest decline in the company’s public-market history. The 240 mg dose produced 11.0 months of progression-free survival compared with 9.5 months for chemotherapy by blinded independent central review, but the difference did not reach statistical significance. A much higher response rate, favorable investigator-assessed progression-free survival and an immature overall-survival trend leave ArriVent with potential arguments for continuing the program, but the company no longer has the clean Phase 3 result investors expected to support a straightforward first-line regulatory strategy.

The setback is especially significant because firmonertinib is ArriVent’s lead asset and had been expected to create a differentiated chemotherapy-free option in a market where Johnson & Johnson’s Rybrevant is already approved with chemotherapy. FURVENT does not invalidate firmonertinib across every EGFR mutation, and ArriVent continues to run the separate Phase 3 ALPACCA study in PACC-mutant lung cancer. With $373.1 million in cash and investments at the end of June and a runway expected into 2028, ArriVent has time to reassess the exon 20 strategy while continuing its other clinical programs rather than being forced into an immediate financing decision.

FURVENT failure removes the clearest route to a first-line chemotherapy-free exon 20 franchise

The commercial opportunity behind FURVENT was straightforward. Firmonertinib is an oral, brain-penetrant EGFR inhibitor, and a positive Phase 3 result could have positioned it as a simpler chemotherapy-free treatment for patients whose tumors carry EGFR exon 20 insertion mutations.

That would have differentiated it from the current U.S. first-line standard involving Rybrevant with carboplatin and pemetrexed. The FDA approved that regimen after the PAPILLON Phase 3 trial showed median progression-free survival of 11.4 months compared with 6.7 months for chemotherapy, representing a 61% reduction in the risk of progression or death.

The comparison with FURVENT is not direct because the studies enrolled different patients at different times and unexpectedly produced very different chemotherapy-control outcomes. Still, the market already has an approved targeted regimen with a conventionally positive randomized trial behind it, raising the evidentiary bar for ArriVent.

Firmonertinib 240 mg generated median progression-free survival of 11.0 months versus 9.5 months for chemotherapy by blinded central review. The hazard ratio was 0.75, but its confidence interval crossed 1.0 and the p-value was 0.0654, leaving the prespecified primary endpoint statistically negative.

The 160 mg dose provided even less support, with median progression-free survival of 8.4 months compared with 9.5 months for chemotherapy. Those results make 240 mg the clear dose of interest while simultaneously reducing the possibility that dose optimization alone can explain the trial failure.

FURVENT’s unexpectedly strong chemotherapy arm is likely to become part of ArriVent’s post-trial analysis. In PAPILLON, chemotherapy produced median PFS of 6.7 months, while the FURVENT central review measured 9.5 months. That difference may partly explain why the trial was harder to win than anticipated, but regulators generally evaluate whether the prespecified trial succeeded rather than whether the control arm outperformed historical expectations.

A 60% response rate gives firmonertinib residual value but cannot erase the failed primary endpoint

FURVENT was not negative across every efficacy measure. By blinded independent review, the confirmed objective response rate reached 60% with firmonertinib 240 mg compared with 33% for chemotherapy, showing that the drug produced substantial tumor shrinkage despite failing to significantly extend central-review PFS.

Investigator assessment also produced a more favorable progression-free survival result. Median PFS reached 11.1 months with the high dose compared with 7.1 months for chemotherapy, corresponding to a hazard ratio of 0.61. Investigator-assessed response rates similarly favored firmonertinib at 61% versus 28%.

Those results explain why ArriVent has not immediately abandoned the program. They indicate that firmonertinib is biologically active and suggest a larger clinical effect than the primary central review captured.

For regulatory purposes, however, the hierarchy matters. Blinded independent central review was selected as the study’s primary PFS assessment partly to reduce variability and potential investigator bias, making the favorable secondary analysis supportive rather than a replacement for the failed endpoint.

Overall survival could become another important variable. ArriVent said the immature data show a trend favoring firmonertinib, although it has not provided the numerical survival results. A compelling mature survival advantage could change how the total dataset is viewed, but the current disclosure is insufficient to conclude that the therapy prolongs life.

Johnson & Johnson has meanwhile reported final PAPILLON follow-up showing median overall survival of 34.3 months with Rybrevant plus chemotherapy compared with 27.9 months for chemotherapy alone. That difference was not statistically significant, but the established first-line regimen now carries several years of efficacy and regulatory experience against which any future firmonertinib strategy will be judged.

ArriVent’s 58% stock collapse reflects how much value investors placed on the exon 20 opportunity

The scale of the share-price reaction shows that FURVENT represented much more than one clinical readout. ArriVent entered the session at $28.46 per share and with a market capitalization of roughly $1.4 billion, but shares quickly fell toward $12 after the results were released.

Fierce Biotech reported that the stock opened down 57% at $12.37, while other market reports showed losses approaching 60% during morning trading. The decline effectively removed hundreds of millions of dollars from ArriVent’s equity valuation in a single session as investors sharply reduced the probability assigned to a successful exon 20 first-line franchise.

The reaction also reflects the economics of ArriVent’s relationship with Shanghai Allist Pharmaceuticals. ArriVent licensed ex-Greater-China rights to firmonertinib and could owe Allist as much as $765 million in development, regulatory and sales milestones, in addition to tiered royalties if the medicine becomes commercially successful. A smaller commercial opportunity or delayed development path would therefore affect both potential revenue and the economic obligations attached to the asset.

ArriVent has not announced a regulatory filing based on FURVENT and instead said it is evaluating the full dataset to determine the most appropriate path forward. That wording leaves several possibilities open, including discussions with regulators, waiting for more mature overall-survival data or reducing investment in the exon 20 program.

What appears much less likely is the straightforward commercial scenario investors had been anticipating before the readout. A statistically successful Phase 3 trial could have supported a strong argument for an oral first-line alternative to Rybrevant plus chemotherapy; the current dataset instead requires ArriVent to explain why favorable secondary evidence should outweigh the negative primary result.

PACC-mutant lung cancer and ArriVent’s ADC pipeline now carry more of the company’s future value

The FURVENT failure does not automatically predict failure in ArriVent’s other pivotal firmonertinib program. ALPACCA is evaluating the drug in patients with P-loop and alpha-C-helix compressing EGFR mutations, collectively known as PACC mutations, which represent a biologically distinct group from exon 20 insertions.

Earlier Phase 1b evidence in first-line PACC-mutant disease showed median progression-free survival of 16.0 months, a confirmed response rate of 68.2% and median duration of response of 14.6 months with firmonertinib 240 mg. Central nervous system responses were also observed, including complete intracranial responses.

Those findings remain early and cannot establish that ALPACCA will succeed, but they mean the commercial thesis for firmonertinib has not disappeared entirely. The Phase 3 program provides an independent opportunity to demonstrate that the drug can address an underserved population with uncommon EGFR mutations.

ArriVent has also been trying to diversify beyond firmonertinib. ARR-217, a CDH17-targeted antibody-drug conjugate for gastrointestinal cancers, has advanced into Phase 1b dose optimization, while ARR-002 is a dual-targeting MUC16/NaPi2b antibody-drug conjugate being developed initially for ovarian and endometrial cancers.

The ADC programs are much earlier than firmonertinib and therefore cannot immediately replace the value lost after FURVENT. Their strategic importance nevertheless increases after a setback to the company’s lead program because investors will increasingly look for evidence that ArriVent can become a multi-asset oncology company rather than remain dependent on a single licensed EGFR inhibitor.

Initial ARR-217 clinical data are one of the company’s upcoming pipeline catalysts. Strong activity could begin shifting part of the investment narrative away from firmonertinib, while disappointing results would leave ArriVent even more dependent on the success of the PACC program.

ArriVent has enough cash to reassess firmonertinib without an immediate financing crisis

One factor separating the FURVENT miss from a potentially existential biotechnology setback is ArriVent’s balance sheet. The company held $373.1 million in cash and investments at the end of the second quarter and said those resources were expected to support planned operations into 2028.

ArriVent used $81.5 million of cash in operating activities during the first six months of 2026, while research and development expenses totaled $80 million. Firmonertinib accounted for approximately $33 million of first-half R&D expense, with spending increasing partly because of the ongoing Phase 3 programs.

A reduction in spending on the exon 20 program could theoretically preserve capital for ALPACCA and the ADC pipeline if management concludes that another large first-line study is not economically justified. Conversely, attempting to rescue the indication through additional trials could consume substantially more capital without guaranteeing a regulatory path.

The collapse in ArriVent’s stock also changes future financing economics. Raising equity after a roughly 58% share-price decline would be significantly more dilutive than financing at the company’s previous valuation, giving management another incentive to manage the existing cash position carefully.

That makes capital allocation one of the most important consequences of FURVENT beyond the immediate clinical disappointment. ArriVent now needs to decide whether additional investment in exon 20 insertion disease offers a better risk-adjusted return than deploying those resources into PACC-mutant NSCLC and the company’s next-generation oncology assets.

Key takeaways from ArriVent’s FURVENT miss and firmonertinib outlook

• FURVENT failed its primary endpoint after firmonertinib 240 mg produced 11.0 months of centrally reviewed PFS versus 9.5 months with chemotherapy.
• The high-dose hazard ratio of 0.75 favored firmonertinib, but a p-value of 0.0654 meant the result was not statistically significant.
• Confirmed response reached 60% with firmonertinib 240 mg versus 33% with chemotherapy, showing meaningful antitumor activity despite the PFS miss.
• Investigator-assessed PFS was more favorable at 11.1 versus 7.1 months, but that secondary analysis cannot replace the failed prespecified primary endpoint.
• ArriVent shares fell roughly 58% toward $12 as investors sharply reduced expectations for a first-line exon 20 commercial franchise.
• Rybrevant plus chemotherapy is already FDA approved in the same setting, making a strong efficacy package important for any future firmonertinib strategy.
• Immature overall-survival data trend in favor of firmonertinib, giving ArriVent another dataset to follow before determining the program’s future.
• The separate ALPACCA Phase 3 trial in PACC-mutant NSCLC remains active and tests firmonertinib in a biologically different EGFR population.
• ArriVent held $373.1 million in cash and investments, providing runway into 2028 while management reassesses development priorities.
• ARR-217 and ARR-002 now carry greater strategic importance as ArriVent works to diversify its value beyond firmonertinib.